Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2B11
- Development stage
- Phase 1
- Lead developer
- China National Biotec
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
2B11 is a human monoclonal antibody developed by China National Biotec Group. It targets the G protein of respiratory syncytial virus (RSV) and has demonstrated both prophylactic and therapeutic efficacy in preclinical models, reducing viral load, leukocyte infiltration, and inflammatory cytokine expression. The drug is being investigated for use in infectious diseases, particularly COVID-19 and other respiratory diseases. Its mechanism involves neutralizing RSV by binding to the G protein, thereby inhibiting viral entry and modulating immune responses.
02
Targets
Beyond the preview
Go deeper on 2B11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2B11.